| Vol. 12.12 – 9 April, 2021 |
| |
|
|
| Scientists report forkhead box protein A1 (FOXA1) as a nonhistone substrate of enhancer of zeste homolog 2 (EZH2), which methylates FOXA1 at lysine-295. [Science Advances] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers established the importance of FOXA1 in neuroendocrine prostate cancer and provided a principled approach to identifying cancer dependencies through epigenomic profiling. [Nature Communications] |
|
|
|
| Knockdown of LINC00261 in PC‐3 cells dramatically attenuated its proliferative and metastatic abilities, which were explained by parallel down‐regulation of CBX2 and FOXA2 through distinct molecular mechanisms. [Molecular Oncology] |
|
|
|
|
Through genomic profiling of prostate cancer (PCa) across various metastatic sites, scientists identified an extremely low frequency of androgen receptor alterations in pulmonary metastasis without liver involvement PCa, high prevalence of DNA damage response pathway deficiency in hepatic metastasis PCa, and high PTEN alteration rates in viscerally-metastatic PCa. [Journal of Urology] |
| | Guava seed polysaccharides (GSPS), GSF1, GSF2, and GSF3 were isolated using Sepharose 6B gel filtration chromatography to assay their inhibitory effects on prostate PC-3 cell growth with direct action or indirect immunotherapy. [International Journal of Molecular Sciences] |
|
|
|
| Knockdown strategies for EPHB2 were performed in prostate cancer cells to analyze the impact on the net lipid balance, proliferation, triacylglycerol-regulating proteins, effect on lipid droplet (LD) biogenesis, and intracellular localization of LDs. [Laboratory Investigation] |
|
|
|
| Investigators revealed an EZH2-SOX9-TNFRSF11A axis in the regulation of activity of NF-κB signaling in prostate cancer cells. [Cancer Cell International] |
|
|
|
| The authors investigated the potential association between autophagy and tau oligomers accumulation and its role in the response of prostate cancer cells to docetaxel. [Journal of Cancer Research and Clinical Oncology] |
|
|
|
| Effects of signal transducer and activator of transcription 3 (STAT3) inhibitors, Stattic and Napabucasin, on metastatic potential in prostate cancer cells were studied in vitro by assessment of migration capacity, self‐renewal potential, and tumorsphere formation. [Prostate] |
|
|
|
|
| Although the current understanding of the biology of ductal adenocarcinoma is limited, genomic analyses have provided insights into the pathology behind its aggressive behavior and potential future therapeutic targets. [Nature Reviews Urology] |
|
|
|
| The authors discuss the immunopathology of the prostate tumor microenvironment, strategies for treating prostate cancer with immunotherapies, and a perspective on potential approaches to enhancing the efficacy of immunotherapies. [Prostate Cancer and Prostatic Diseases] |
|
|
|
|
| NorthShore University HealthSystem and GoPath Laboratories announced a novel partnership to launch a new genetics test that assessed the inherited risk for prostate cancer using three methods: family history, rare pathogenic mutations, and genetic risk score. [NorthShore University HealthSystem (PR Newswire, LLC.)] |
|
|
|
| Advaxis, Inc. has announced an agreement with Columbia University Irving Medical Center to fund a Phase I clinical study evaluating ADXS-504 in patients with biochemically recurrent prostate cancer. The study will be the first clinical evaluation of ADXS-504, Advaxis’ off-the-shelf neoantigen immunotherapy drug candidate for early prostate cancer. [Advaxis, Inc.] |
|
|
|
|
| May 25 – 27, 2022 Hinxton, England, United Kingdom |
|
|
|
|
|
| The University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| Virginia Commonwealth University – Richmond, Virginia, United States |
|
|
|
|
| University of Calgary – Calgary, Alberta, Canada |
|
|
|
| Duke University – Durham, North Carolina, United States |
|
|
|
|